Condition (MeSH)
Arrhythmogenic Right Ventricular Dysplasia
ClinicalTrials.gov lists 47 trials for Arrhythmogenic Right Ventricular Dysplasia or a narrower condition beneath it. Lexeo Therapeutics has the most among industry and government lead sponsors, with 3.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
47 of the 47 trials are tagged with Arrhythmogenic Right Ventricular Dysplasia itself; the rest are tagged with a narrower condition beneath it.
When did Arrhythmogenic Right Ventricular Dysplasia trials start? (20)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Not applicable
- Observational
Top of scale: 6
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 3 |
| 2025 | 4 |
| 2024 | 6 |
| 2023 | 6 |
| 2022 | 1 |
| 2021 | 3 |
| 2020 | 1 |
| 2019 | 2 |
| 2018 | 3 |
| 2017 | 2 |
Showing 10 of 20 earlier years.
No forecast is made for this condition: it averages 4.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Prediction, not a registry value: median of 36 months from start to primary completion across 6 trials still running at the 2026-10-09 snapshot; registered median of 64 months across 13 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Arrhythmogenic Right Ventricular Dysplasia trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 2 |
| Phase 1/2 | 2 |
| Phase 2 | 3 |
| Not applicable | 8 |
| Observational | 32 |
How many Arrhythmogenic Right Ventricular Dysplasia trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 3 |
| Recruiting | 19 |
| Enrolling by invitation | 4 |
| Active, not recruiting | 1 |
| Completed | 11 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Arrhythmogenic Right Ventricular Dysplasia trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Lexeo Therapeutics | 3 |
| Rocket Pharmaceuticals Inc. | 2 |
| Tenaya Therapeutics | 2 |
| China National Center for Cardiovascular Diseases | 1 |
Which drugs are being tested for Arrhythmogenic Right Ventricular Dysplasia? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| IC14 | 1 |
| .spironolactone | 1 |
| Flecainide | 1 |
| Tideglusib | 1 |
Interventions as named in the registry (6)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Immunological assessment carried out on intracardiac material | 1 |
| Peripheral immunological assessment on venous blood | 1 |
| MRI | 1 |
| Exercise | 1 |
| PET/CT ([F-18]FAPI-74) | 1 |
Showing 5 of 6 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Arrhythmogenic Right Ventricular Dysplasia trials report? (2)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Ventricular tachycardia requiring implantabale cardioverter defibrillator (ICD) therapy | 2 | 1 |
| no adverse events recorded† | 0 | 1 |
Which publications cover Arrhythmogenic Right Ventricular Dysplasia? (100)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. | International journal of cardiology | 2024 | Yes |
| 2023 ESC Guidelines for the management of cardiomyopathies. | European heart journal | 2023 | Yes |
| Multimodality Imaging in Arrhythmogenic Right Ventricular Cardiomyopathy. | Circulation. Cardiovascular imaging | 2022 | Yes |
| Age-related differences and associated mid-term outcomes of subcutaneous implantable cardioverter-defibrillators: A propensity-matched analysis from a multicenter European registry. | Heart rhythm | 2022 | Yes |
| Arrhythmogenic Right Ventricular Cardiomyopathy. | JACC. Clinical electrophysiology | 2022 | Yes |
Showing 5 of 100 publications.
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Inherited arrhythmogenic cardiomyopathy | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Exact |
| Inherited arrhythmogenic cardiomyopathy | Point prevalence | 1-5 / 10 000 | Italy | Not stated | Exact |
| Inherited arrhythmogenic cardiomyopathy | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Unspecified |
| Inherited arrhythmogenic cardiomyopathy | Point prevalence | 1-5 / 10 000 | Worldwide | Not stated | Exact |
| Inherited arrhythmogenic cardiomyopathy | Point prevalence | 1-5 / 10 000 | Italy | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Inherited arrhythmogenic cardiomyopathy | 247 | Exact | Orphadata Science knowledge files, Product 1 |
| Inherited arrhythmogenic cardiomyopathy | 247 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.